FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / PLoS Pathog / Getting to grips with strangles: an effective multi-componen...
PLoS pathogens2009; 5(9); e1000584; doi: 10.1371/journal.ppat.1000584

Getting to grips with strangles: an effective multi-component recombinant vaccine for the protection of horses from Streptococcus equi infection.

Abstract: Streptococcus equi subspecies equi (S. equi) is a clonal, equine host-adapted pathogen of global importance that causes a suppurative lymphodendopathy of the head and neck, more commonly known as Strangles. The disease is highly prevalent, can be severe and is highly contagious. Antibiotic treatment is usually ineffective. Live attenuated vaccine strains of S. equi have shown adverse reactions and they suffer from a short duration of immunity. Thus, a safe and effective vaccine against S. equi is highly desirable. The bacterium shows only limited genetic diversity and an effective vaccine could confer broad protection to horses throughout the world. Welsh mountain ponies (n = 7) vaccinated with a combination of seven recombinant S. equi proteins were significantly protected from experimental infection by S. equi, resembling the spontaneous disease. Vaccinated horses had significantly reduced incidence of lymph node swelling (p = 0.0013) lymph node abscessation (p = 0.00001), fewer days of pyrexia (p = 0.0001), reduced pathology scoring (p = 0.005) and lower bacterial recovery from lymph nodes (p = 0.004) when compared with non-vaccinated horses (n = 7). Six of 7 vaccinated horses were protected whereas all 7 non-vaccinated became infected. The protective antigens consisted of five surface localized proteins and two IgG endopeptidases. A second vaccination trial (n = 7+7), in which the IgG endopeptidases were omitted, demonstrated only partial protection against S. equi, highlighting an important role for these vaccine components in establishing a protective immune response. S. equi shares >80% sequence identity with Streptococcus pyogenes. Several of the components utilized here have counterparts in S. pyogenes, suggesting that our findings have broader implications for the prevention of infection with this important human pathogen. This is one of only a few demonstrations of protection from streptococcal infection conferred by a recombinant multi-component subunit vaccine in a natural host.
Get Full Text
Publication Date: 2009-09-18 PubMed ID: 19763180PubMed Central: PMC2736577DOI: 10.1371/journal.ppat.1000584Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research focuses on testing the effectiveness of a recombinant vaccine made up of multiple components aimed at protecting horses from Streptococcus equi (S. equi) infection, a contagious disease widely known as Strangles. The experimental results show that the vaccine effectively reduces the symptoms and severity of Strangles in horses.

Study Background

  • Strangles, caused by the globally important pathogen S. equi, is a prevalent disease affecting horses that causes a suppurative lymphodendopathy of the head and neck. The disease is highly infectious and can be severe.
  • Current treatments, including antibiotic use and live attenuated vaccine strains of S. equi, are mostly ineffective due to adverse reactions and a short duration of immunity.
  • The study emphasizes the need for a safe and effective vaccine that can offer broad protection to horses worldwide against this highly contagious disease.

Methodology and Findings

  • A group of Welsh mountain ponies was vaccinated with a combination of seven recombinant S. equi proteins. These horses showed significant protection against experimental S. equi infection, resembling the spontaneous disease.
  • Compared with non-vaccinated horses, the vaccinated horses showed significantly reduced lymph node swelling and abscessation, fewer days of pyrexia (fever), lower pathology scores, and reduced bacterial recovery from lymph nodes.
  • Besides, out of seven vaccinated horses, six were protected, while all seven non-vaccinated horses got infected.
  • The protective antigens in the vaccine included five surface-localized proteins and two IgG endopeptidases.

Second Vaccination Trial and Conclusions

  • A second trial excluding the IgG endopeptidases from the vaccine showed only partial protection against S. equi, emphasizing the importance of these components in establishing protective immunity.
  • As S. equi shares more than 80% sequence identity with Streptococcus pyogenes, several components used in this research also have counterparts in S. pyogenes, a human pathogen. This suggests broader implications for preventing infections with S. pyogenes among humans.
  • This study is among the few to show that a multi-component recombinant subunit vaccine can provide protection from streptococcal infections in a natural host.

Cite This Article

APA
Guss B, Flock M, Frykberg L, Waller AS, Robinson C, Smith KC, Flock JI. (2009). Getting to grips with strangles: an effective multi-component recombinant vaccine for the protection of horses from Streptococcus equi infection. PLoS Pathog, 5(9), e1000584. https://doi.org/10.1371/journal.ppat.1000584

Publication

PLoS pathogens
ISSN: 1553-7374
NlmUniqueID: 101238921
Country: United States
Language: English
Volume: 5
Issue: 9
Pages: e1000584

Researcher Affiliations

Guss, Bengt
  • Department of Microbiology, Swedish University of Agricultural Sciences, Uppsala, Sweden.
Flock, Margareta
    Frykberg, Lars
      Waller, Andrew S
        Robinson, Carl
          Smith, Ken C
            Flock, Jan-Ingmar

              MeSH Terms

              • Animals
              • Bacterial Proteins / immunology
              • Disease Models, Animal
              • Female
              • Fever / prevention & control
              • Fever / veterinary
              • Horse Diseases / immunology
              • Horse Diseases / prevention & control
              • Horses
              • Lymph Nodes / microbiology
              • Lymph Nodes / pathology
              • Mice
              • Mice, Inbred Strains
              • Streptococcal Infections / immunology
              • Streptococcal Infections / prevention & control
              • Streptococcal Infections / veterinary
              • Streptococcal Vaccines / administration & dosage
              • Streptococcal Vaccines / immunology
              • Streptococcus equi / immunology
              • Vaccination / veterinary
              • Vaccines, Synthetic / administration & dosage
              • Vaccines, Synthetic / immunology

              Conflict of Interest Statement

              The authors have declared that no competing interests exist.

              References

              This article includes 38 references
              1. Bambini S, Rappuoli R. The use of genomics in microbial vaccine development.. Drug Discov Today 2009;14:252–260.
                pmc: PMC7108364pubmed: 19150507
              2. Serruto D, Serino L, Masignani V, Pizza M. Genome-based approaches to develop vaccines against bacterial pathogens.. Vaccine 2009.
                pubmed: 19200820
              3. Jacobs AA, Goovaerts D, Nuijten PJ, Theelen RP, Hartford OM. Investigations towards an efficacious and safe strangles vaccine: submucosal vaccination with a live attenuated Streptococcus equi.. Vet Rec 2000;147:563–567.
                pubmed: 11104039
              4. Kemp-Symonds J, Kemble T, Waller A. Modified live Streptococcus equi (‘strangles’) vaccination followed by clinically adverse reactions associated with bacterial replication.. Equine Vet J 2007;39:284–286.
                pubmed: 17520983
              5. Newton R, Waller A, King A. Investigation of suspected adverse reactions following strangles vaccination in horses.. Vet Rec 2005;156:291–292.
                pubmed: 15765905
              6. Webb K, Jolley KA, Mitchell Z, Robinson C, Newton JR. Development of an unambiguous and discriminatory multilocus sequence typing scheme for the Streptococcus zooepidemicus group.. Microbiology 2008;154:3016–3024.
                pubmed: 18832307
              7. Flock M, Jacobsson K, Frykberg L, Hirst TR, Franklin A. Recombinant Streptococcus equi proteins protect mice in challenge experiments and induce immune response in horses.. Infect Immun 2004;72:3228–3236.
                pmc: PMC415648pubmed: 15155624
              8. Lindmark H, Jonsson P, Engvall E, Guss B. Pulsed-field gel electrophoresis and distribution of the genes zag and fnz in isolates of Streptococcus equi.. Res Vet Sci 1999;66:93–99.
                pubmed: 10208886
              9. Karlstrom A, Jacobsson K, Guss B. SclC is a member of a novel family of collagen-like proteins in Streptococcus equi subspecies equi that are recognised by antibodies against SclC.. Vet Microbiol 2006;114:72–81.
                pubmed: 16384667
              10. Lannergård J, Frykberg L, Guss B. CNE, a collagen-binding protein of Streptococcus equi.. FEMS Microbiol Lett 2003;16:69–74.
                pubmed: 12757948
              11. Waller A, Flock M, Smith K, Robinson C, Mitchell Z. Vaccination of horses against strangles using recombinant antigens from Streptococcus equi.. Vaccine 2007;25:3629–3635.
                pubmed: 17321016
              12. Karlström Å, Jacobsson K, Flock M, Flock J-I. Identification of a novel collagen-like protein, SclC, in Streptococcus equi using signal sequence phage display.. Vet Microbiol 2004;104:179–188.
                pubmed: 15564026
              13. Holden MT, Heather Z, Paillot R, Steward KF, Webb K. Genomic evidence for the evolution of Streptococcus equi: host restriction, increased virulence, and genetic exchange with human pathogens.. PLoS Pathog 2009;5:e1000346.
                doi: 10.1371/journal.ppat.1000346pmc: PMC2654543pubmed: 19325880google scholar: lookup
              14. Jacobsson K, Jonsson H, Lindmark H, Guss B, Lindberg M. Shot-gun phage display mapping of two streptococcal cell-surface proteins.. Microbiol Res 1997;152:121–128.
                pubmed: 9265766
              15. Beres SB, Sesso R, Pinto SW, Hoe NP, Porcella SF. Genome sequence of a Lancefield group C Streptococcus zooepidemicus strain causing epidemic nephritis: new information about an old disease.. PLoS ONE 2008;3:e3026.
                doi: 10.1371/journal.pone.0003026pmc: PMC2516327pubmed: 18716664google scholar: lookup
              16. Lannergard J, Guss B. IdeE, an IgG-endopeptidase of Streptococcus equi ssp. equi.. FEMS Microbiol Lett 2006;262:230–235.
                pubmed: 16923080
              17. Timoney JF, Yang J, Liu J, Merant C. IdeE reduces the bactericidal activity of equine neutrophils for Streptococcus equi.. Vet Immunol Immunopathol 2008;122:76–82.
                pubmed: 18077002
              18. Lannergard J, Flock M, Johansson S, Flock JI, Guss B. Studies of fibronectin-binding proteins of Streptococcus equi.. Infect Immun 2005;73:7243–7251.
                pmc: PMC1273847pubmed: 16239519
              19. Hulting G, Flock M, Frykberg L, Lannergård J, Flock J-I. Two novel IgG endopeptidases of Streptococcus equi. FEMS Microbiol Letters In press. 2009.
                pubmed: 19659725
              20. Flock M, Karlstrom A, Lannergard J, Guss B, Flock JI. Protective effect of vaccination with recombinant proteins from Streptococcus equi subspecies equi in a strangles model in the mouse.. Vaccine 2006;24:4144–4151.
                pubmed: 16580099
              21. Kelly C, Bugg M, Robinson C, Mitchell Z, Davis-Poynter N. Sequence variation of the SeM gene of Streptococcus equi allows discrimination of the source of strangles outbreaks.. J Clin Microbiol 2006;44:480–486.
                pmc: PMC1392674pubmed: 16455902
              22. Nakata M, Koller T, Moritz K, Ribardo D, Jonas L. Mode of expression and functional characterization of FCT-3 pilus region-encoded proteins in Streptococcus pyogenes serotype M49.. Infect Immun 2009;77:32–44.
                pmc: PMC2612252pubmed: 18852238
              23. Godehardt AW, Hammerschmidt S, Frank R, Chhatwal GS. Binding of alpha2-macroglobulin to GRAB (Protein G-related alpha2-macroglobulin-binding protein), an important virulence factor of group A streptococci, is mediated by two charged motifs in the DeltaA region.. Biochem J 2004;381:877–885.
                pmc: PMC1133899pubmed: 15113281
              24. Jonsson H, Lindmark H, Guss B. A protein G-related cell surface protein in Streptococcus zooepidemicus.. Infect Immun 1995;63:2968–2975.
                pmc: PMC173403pubmed: 7542636
              25. Lei B, DeLeo FR, Hoe NP, Graham MR, Mackie SM. Evasion of human innate and acquired immunity by a bacterial homolog of CD11b that inhibits opsonophagocytosis.. Nat Med 2001;7:1298–1305.
                pubmed: 11726969
              26. Soderberg JJ, von Pawel-Rammingen U. The streptococcal protease IdeS modulates bacterial IgGFc binding and generates 1/2Fc fragments with the ability to prime polymorphonuclear leucocytes.. Mol Immunol 2008;45:3347–3353.
                pubmed: 18533265
              27. Akesson P, Moritz L, Truedsson M, Christensson B, von Pawel-Rammingen U. IdeS, a highly specific immunoglobulin G (IgG)-cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection.. Infect Immun 2006;74:497–503.
                pmc: PMC1346671pubmed: 16369006
              28. Dinkla K, Sastalla I, Godehardt AW, Janze N, Chhatwal GS. Upregulation of capsule enables Streptococcus pyogenes to evade immune recognition by antigen-specific antibodies directed to the G-related alpha2-macroglobulin-binding protein GRAB located on the bacterial surface.. Microbes Infect 2007;9:922–931.
                pubmed: 17544803
              29. Mora M, Bensi G, Capo S, Falugi F, Zingaretti C. Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens.. Proc Natl Acad Sci U S A 2005;102:15641–15646.
                pmc: PMC1253647pubmed: 16223875
              30. Okamoto S, Tamura Y, Terao Y, Hamada S, Kawabata S. Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group: a Streptococcus challenge in mice.. Vaccine 2005;23:4852–4859.
                pubmed: 15990202
              31. Timoney JF, Qin A, Muthupalani S, Artiushin S. Vaccine potential of novel surface exposed and secreted proteins of Streptococcus equi.. Vaccine 2007;25:5583–5590.
                pubmed: 17360081
              32. Timoney JF, Kumar P. Early pathogenesis of equine Streptococcus equi infection (strangles).. Equine Vet J 2008;40:637–642.
                pubmed: 19165932
              33. Florindo HF, Pandit S, Goncalves LM, Alpar HO, Almeida AJ. New approach on the development of a mucosal vaccine against strangles: Systemic and mucosal immune responses in a mouse model.. Vaccine 2009;27:1230–1241.
                pubmed: 19114079
              34. Florindo HF, Pandit S, Lacerda L, Goncalves LM, Alpar HO. The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-epsilon-caprolactone-based nanoparticles.. Biomaterials 2009;30:879–891.
                pubmed: 19027152
              35. Morein B, Hu KF, Abusugra I. Current status and potential application of ISCOMs in veterinary medicine.. Adv Drug Deliv Rev 2004;56:1367–1382.
                pubmed: 15191787
              36. Hamilton A, Robinson C, Sutcliffe IC, Slater J, Maskell DJ. Mutation of the maturase lipoprotein attenuates the virulence of Streptococcus equi to a greater extent than does loss of general lipoprotein lipidation.. Infect Immun 2006;74:6907–6919.
                pmc: PMC1698103pubmed: 17015455
              37. Lindmark H, Nilsson M, Guss B. Comparison of the fibronectin-binding protein FNE from Streptococcus equi subspecies equi with FNZ from S. equi subspecies zooepidemicus reveals a major and conserved difference.. Infect Immun 2001;69:3159–3163.
                pmc: PMC98272pubmed: 11292736
              38. Lindmark H, Guss B. SFS, a novel fibronectin-binding protein from Streptococcus equi, inhibits the binding between fibronectin and collagen.. Infect Immun 1999;67:2383–2388.
                pmc: PMC115982pubmed: 10225899

              Citations

              This article has been cited 12 times.
              1. Righetti F, Hentrich K, Flock M, Frosth S, Jacobsson K, Bjerketorp J, Pathak A, Ido N, Henriques-Normark B, Frykberg L, Paillot R, Guss B, Wood T, Flock JI, Waller AS. Neutralisation of the Immunoglobulin-Cleaving Activity of Streptococcus equi Subspecies equi IdeE by Blood Sera from Ponies Vaccinated with a Multicomponent Protein Vaccine. Vaccines (Basel) 2025 Oct 17;13(10).
                doi: 10.3390/vaccines13101061pubmed: 41150447google scholar: lookup
              2. Rotinsulu DA, Ewers C, Kerner K, Amrozi A, Soejoedono RD, Semmler T, Bauerfeind R. Molecular Features and Antimicrobial Susceptibilities of Streptococcus equi ssp. equi Isolates from Strangles Cases in Indonesia. Vet Sci 2023 Jan 10;10(1).
                doi: 10.3390/vetsci10010049pubmed: 36669050google scholar: lookup
              3. Siggins MK, Sriskandan S. Bacterial Lymphatic Metastasis in Infection and Immunity. Cells 2021 Dec 23;11(1).
                doi: 10.3390/cells11010033pubmed: 35011595google scholar: lookup
              4. Dominguez-Medina CC, Rash NL, Robillard S, Robinson C, Efstratiou A, Broughton K, Parkhill J, Holden MTG, Lopez-Alvarez MR, Paillot R, Waller AS. SpeS: A Novel Superantigen and Its Potential as a Vaccine Adjuvant against Strangles. Int J Mol Sci 2020 Jun 23;21(12).
                doi: 10.3390/ijms21124467pubmed: 32586031google scholar: lookup
              5. Charbonneau ARL, Taylor E, Mitchell CJ, Robinson C, Cain AK, Leigh JA, Maskell DJ, Waller AS. Identification of genes required for the fitness of Streptococcus equi subsp. equi in whole equine blood and hydrogen peroxide. Microb Genom 2020 Apr;6(4).
                doi: 10.1099/mgen.0.000362pubmed: 32228801google scholar: lookup
              6. D'Gama JD, Ma Z, Zhang H, Liu X, Fan H, Morris ERA, Cohen ND, Cywes-Bentley C, Pier GB, Waldor MK. A Conserved Streptococcal Virulence Regulator Controls the Expression of a Distinct Class of M-Like Proteins. mBio 2019 Oct 22;10(5).
                doi: 10.1128/mBio.02500-19pubmed: 31641092google scholar: lookup
              7. Boyle AG, Timoney JF, Newton JR, Hines MT, Waller AS, Buchanan BR. Streptococcus equi Infections in Horses: Guidelines for Treatment, Control, and Prevention of Strangles-Revised Consensus Statement. J Vet Intern Med 2018 Mar;32(2):633-647.
                doi: 10.1111/jvim.15043pubmed: 29424487google scholar: lookup
              8. Lukomski S, Bachert BA, Squeglia F, Berisio R. Collagen-like proteins of pathogenic streptococci. Mol Microbiol 2017 Mar;103(6):919-930.
                doi: 10.1111/mmi.13604pubmed: 27997716google scholar: lookup
              9. Spoerry C, Hessle P, Lewis MJ, Paton L, Woof JM, von Pawel-Rammingen U. Novel IgG-Degrading Enzymes of the IgdE Protease Family Link Substrate Specificity to Host Tropism of Streptococcus Species. PLoS One 2016;11(10):e0164809.
                doi: 10.1371/journal.pone.0164809pubmed: 27749921google scholar: lookup
              10. Lynskey NN, Banerji S, Johnson LA, Holder KA, Reglinski M, Wing PA, Rigby D, Jackson DG, Sriskandan S. Rapid Lymphatic Dissemination of Encapsulated Group A Streptococci via Lymphatic Vessel Endothelial Receptor-1 Interaction. PLoS Pathog 2015 Sep;11(9):e1005137.
                doi: 10.1371/journal.ppat.1005137pubmed: 26352587google scholar: lookup
              11. Harris SR, Robinson C, Steward KF, Webb KS, Paillot R, Parkhill J, Holden MT, Waller AS. Genome specialization and decay of the strangles pathogen, Streptococcus equi, is driven by persistent infection. Genome Res 2015 Sep;25(9):1360-71.
                doi: 10.1101/gr.189803.115pubmed: 26160165google scholar: lookup
              12. Flock M, Frykberg L, Sköld M, Guss B, Flock JI. Antiphagocytic function of an IgG glycosyl hydrolase from Streptococcus equi subsp. equi and its use as a vaccine component. Infect Immun 2012 Aug;80(8):2914-9.
                doi: 10.1128/IAI.06083-11pubmed: 22615244google scholar: lookup
              Subscribe to our newsletter
              Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.